Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
abemaciclib + lasofoxifene
- Development stage
- Unknown
- Lead developer
- Sermonix Pharmaceuticals
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Abemaciclib + lasofoxifene is an investigational oral combination therapy for the treatment of estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2-) metastatic breast cancer with acquired resistance due to ESR1 mutations. Abemaciclib is a small molecule inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), which blocks cell cycle progression in cancer cells. Lasofoxifene is a selective estrogen receptor modulator (SERM) that antagonizes mutant forms of the estrogen receptor alpha, particularly those harboring ESR1 mutations that confer resistance to standard endocrine therapies. The combination aims to overcome endocrine resistance and improve clinical outcomes in patients who have progressed after prior endocrine therapy and CDK4/6 inhibitors[3][4][9].
- Other names
- abemaciclib + lasofoxifene
02
Targets
CDK6 (Cyclin-dependent kinase 6)ESR1 (ERα)CDK4 (Cyclin-dependent kinase 4)
Beyond the preview
Go deeper on abemaciclib + lasofoxifene.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on abemaciclib + lasofoxifene.